- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 30, 2020
Highlights
- Market Cap
- $106.04M
- Enterprise Value
- $73.34M
- EPS (TTM)
- -$2.10
- Gross Profit (TTM)
- -$20.00K
- EBITDA (TTM)
- -$45.87M
- Year Range
- $2.14 - $11.88
- Target Price
- $18.67
- ROA (TTM)
- -40.16%
- ROE (TTM)
- -64.32%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KLRS Performance Chart
Kalaris Therapeutics, Inc (KLRS) is down 47.0% since the beginning of the year. At $4 per share, KLRS is trading 62.4% below its 52-week high of $12. Investors who bought $1,000 worth of KLRS shares 5 years ago would now be looking at an investment worth $9.
Loading charts...
Returns By Period
Kalaris Therapeutics, Inc (KLRS) has returned -47.04% so far this year and 89.41% over the past 12 months.
Kalaris Therapeutics, Inc
- 1D
- 1.59%
- 1M
- -9.15%
- YTD
- -47.04%
- 6M
- -53.73%
- 1Y
- 89.41%
- 3Y*
- -61.01%
- 5Y*
- -60.84%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
KLRS Monthly Returns History
Based on dividend-adjusted daily data since Jul 30, 2020, KLRS's average daily return is -0.11%, while the average monthly return is -3.07%.
Historically, 44% of months were positive and 56% were negative. The best month was Aug 2022 with a return of +63.6%, while the worst month was Dec 2023 at -63.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, KLRS closed higher 46% of trading days. The best single day was Sep 16, 2025 with a return of +35.0%, while the worst single day was Dec 22, 2023 at -67.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.21% | 17.79% | -44.84% | -4.33% | -4.53% | -15.18% | -47.04% | ||||||
| 2025 | -2.48% | 4.03% | -18.06% | -21.92% | -53.75% | -7.93% | 0.37% | 52.24% | 41.67% | -12.98% | 24.06% | 35.26% | -12.63% |
| 2024 | 5.91% | 2.31% | 2.48% | 5.23% | -4.97% | -4.19% | 2.45% | 5.17% | 3.75% | 15.03% | -41.08% | -23.36% | -38.22% |
| 2023 | 12.67% | 16.78% | -41.63% | -12.69% | 9.59% | -9.81% | -3.24% | -4.86% | -31.31% | -30.23% | 25.33% | -63.84% | -86.75% |
| 2022 | -36.94% | 10.29% | -25.00% | -32.59% | -14.95% | 0.78% | 17.69% | 63.62% | 5.06% | -12.17% | 8.37% | -31.69% | -60.36% |
| 2021 | -4.86% | -0.03% | -36.00% | 0.98% | -0.80% | -15.78% | -3.04% | 0.57% | 30.18% | -4.19% | -27.28% | -25.89% | -66.34% |
Benchmark Metrics
Kalaris Therapeutics, Inc has an annualized alpha of -38.28%, beta of 1.38, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since July 30, 2020.
- This stock participated in 181.39% of S&P 500 Index downside but only -76.79% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -38.28%
- Beta
- 1.38
- R²
- 0.06
- Upside Capture
- -76.79%
- Downside Capture
- 181.39%
Return for Risk
Risk / Return Rank
KLRS ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Kalaris Therapeutics, Inc (KLRS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KLRS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.96 | ||
| Sortino ratioReturn per unit of downside risk | -0.52 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.32 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 1.43 | 2.46 | -1.02 |
| Martin ratioReturn relative to average drawdown | 2.89 | 10.92 | -8.03 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Kalaris Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kalaris Therapeutics, Inc was 99.79%, occurring on Aug 14, 2025. The portfolio has not yet recovered.
The current Kalaris Therapeutics, Inc drawdown is 99.58%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -99.79%Aug 2025 | 4y 8mo | — | 5y 6moDec 2020 - now |
2020 bear market2020 | -50.70%Sep 2020 | 1mo 4d | 2mo 19d | 3mo 23dAug 2020 - Dec 2020 |
2020 pullback2020 | -1.93%Jul 2020 | 0s | 3d | 3dJul 2020 - Aug 2020 |
Drawdown Indicators
| KLRS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.79% | -56.78% | -43.01% |
Max Drawdown (1Y)Largest decline over 1 year | -62.80% | -9.10% | -53.70% |
Max Drawdown (3Y)Largest decline over 3 years | -97.29% | -18.90% | -78.39% |
Max Drawdown (5Y)Largest decline over 5 years | -99.62% | -25.43% | -74.19% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.58% | -3.21% | -96.37% |
Average DrawdownAverage peak-to-trough decline | -81.35% | -10.71% | -70.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.08% | 2.04% | +29.04% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Kalaris Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Kalaris Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for KLRS in comparison with other companies in the Biotechnology industry. Currently, KLRS has a P/B value of 1.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KLRS
Add Kalaris Therapeutics, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KLRS